Bone Marrow Research [44] “Guidelines for the diagnosis and management of multiple myeloma,” British Committee for standards in haematology in conjunction with the UK myeloma forum, September 2010. [45] T. Eriksson, S. Bjo¨rkman, and P. Ho¨glund, “Clinical pharma- cology of thalidomide,” European Journal of Clinical Pharma- cology, vol. 57, no. 5, pp. 365–376, 2001. [46] T. Eriksson, P. Ho¨glund, I. Turesson et al., “Pharmacokinetics of thalidomide in patients with impaired renal function and while on and oﬀ dialysis,” Journal of Pharmacy and Pharmacology, vol. 55, no. 12, pp. 1701–1706, 2003. [47] P. G. Richardson, E. Blood, C. S. Mitsiades et al., “A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma,” Blood, vol. 108, no. 10, pp. 3458–3464, 2006. [48] M. Dimopoulos, A. Spencer, M. Attal et al., “Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma,” New England Journal of Medicine, vol. 357, no. 21, pp. 2123–2132, 2007. [49] D. M. Weber, C. Chen, R. Niesvizky et al., “Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America,” New England Journal of Medicine, vol. 357, no. 21, pp. 2133–2142, 2007. [50] S. V. Rajkumar, S. R. Hayman, M. Q. Lacy et al., “Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma,” Blood, vol. 106, no. 13, pp. 4050– 4053, 2005. [51] C. S. Mitsiades and N. Mitsiades, “CC-5013 (Celgene),” Current Opinion in Investigational Drugs, vol. 5, no. 6, pp. 635– 647, 2004. [52] N. Chen, H. Lau, L. Kong et al., “Pharmacokinetics of lenalidomide in subjects with various degrees of renal impair- ment and in subjects on hemodialysis,” Journal of Clinical Pharmacology, vol. 47, no. 12, pp. 1466–1475, 2007. [53] J. Adams and M. Kauﬀman, “Development of the proteasome inhibitor VelcadeTM (Bortezomib),” Cancer Investigation, vol. 22, no. 2, pp. 304–311, 2004. [54] B. C. McLeod, “Introduction to the third special issue: clinical applications of therapeutic apheresis,” Journal of Clinical Apheresis, vol. 15, no. 1-2, pp. 1–5, 2000. [55] W. F. Clark, A. K. Stewart, G. A. Rock et al., “Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial,” Annals of Internal Medicine, vol. 143, no. 11, pp. 777–784, 2005. [56] P. Zucchelli, S. Pasquali, L. Cagnoli, and G. Ferrari, “Con- trolled plasma exchange trial in acute renal failure due to multiple myeloma,” Kidney International, vol. 33, no. 6, pp. 1175–1180, 1988. [57] W. J. Johnson, R. A. Kyle, A. A. Pineda, P. C. O’Brien, and K. E. Holley, “Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy,” Archives of Internal Medicine, vol. 150, no. 4, pp. 863–869, 1990. [58] C. Cserti, R. Haspel, C. Stowell, and W. Dzik, “Light- chain removal by plasmapheresis in myeloma-associated renal failure,” Transfusion, vol. 47, no. 3, pp. 511–514, 2007. [59] C. A. Hutchison, P. Cockwell, S. Reid et al., “Eﬃcient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 886–895, 2007. [60] C. A. Hutchison, M. Cook, N. Heyne et al., “European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial,” Trials, vol. 9, article no. 55, 2008. 9